U.S. markets close in 21 minutes
  • S&P 500

    4,592.29
    +53.86 (+1.19%)
     
  • Dow 30

    35,221.01
    +640.93 (+1.85%)
     
  • Nasdaq

    15,227.31
    +141.84 (+0.94%)
     
  • Russell 2000

    2,211.47
    +52.16 (+2.42%)
     
  • Crude Oil

    69.61
    +3.35 (+5.06%)
     
  • Gold

    1,780.10
    -3.80 (-0.21%)
     
  • Silver

    22.36
    -0.12 (-0.52%)
     
  • EUR/USD

    1.1287
    -0.0031 (-0.27%)
     
  • 10-Yr Bond

    1.4340
    +0.0910 (+6.78%)
     
  • GBP/USD

    1.3256
    +0.0020 (+0.15%)
     
  • USD/JPY

    113.4620
    +0.6620 (+0.59%)
     
  • BTC-USD

    49,146.93
    +384.05 (+0.79%)
     
  • CMC Crypto 200

    1,270.57
    +10.41 (+0.83%)
     
  • FTSE 100

    7,232.28
    +109.96 (+1.54%)
     
  • Nikkei 225

    27,927.37
    -102.20 (-0.36%)
     

Poseida Therapeutics to Present at BofA Securities 2021 Virtual Health Care Conference

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SAN DIEGO, May 5, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company's CEO, Eric Ostertag, MD, PhD, will present at the BofA Securities 2021 Virtual Health Care Conference on Wednesday, May 12, 2021 at 2:45pm ET.

Poseida Therapeutics (PRNewsfoto/Poseida Therapeutics, Inc.)
Poseida Therapeutics (PRNewsfoto/Poseida Therapeutics, Inc.)

A webcast of the presentation will be available on the Investors & Media Section of the Poseida website, www.poseida.com. An archived replay of the webcast will be available for approximately 30 days following each presentation.

About Poseida Therapeutics, Inc.

Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our core proprietary platforms, including our non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. Our core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable us to engineer our wholly-owned portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics. To learn more, visit www.poseida.com and connect with us on Twitter and LinkedIn.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the potential benefits of Poseida's technology platforms and product candidates, Poseida's plans and strategy with respect to developing its technologies and product candidates and anticipated timelines and milestones with respect to Poseida's development programs. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Poseida's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with development and regulatory approval of novel product candidates in the biopharmaceutical industry and the other risks described in Poseida's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Poseida undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/poseida-therapeutics-to-present-at-bofa-securities-2021-virtual-health-care-conference-301283758.html

SOURCE Poseida Therapeutics, Inc.